Vor Biopharma reports preliminary cash of ~$450M as of Dec 31, 2025

Vor Biopharma Inc.

Cash, cash equivalents and short-term investments ~$450M as of Dec 31, 2025 (preliminary, unaudited).
Company presenting at 44th Annual J.P. Morgan Healthcare Conference on Jan 13, 2026.
Financial data is subject to change upon completion of audited FY 2025 statements.

item 2.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.